These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 15605767

  • 1. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
    Rukavitsyn OA, Pop VP, Seriakov AP.
    Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
    [Abstract] [Full Text] [Related]

  • 2. The management of elderly patients with myeloproliferative disorders.
    Tura S.
    Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R, Marzetta K, Miglioranza A, Redaelli S, Maino C, Maffiolini A, Gorini M.
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [Abstract] [Full Text] [Related]

  • 5. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
    Kvasnicka HM, Thiele J.
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
    [Abstract] [Full Text] [Related]

  • 6. [Polycythemia vera as a multiphasic clonal panmyelopathy: diagnostic profile, chronic pathological progression and effect of therapy on the survival of 74 cases].
    Sánchez Fayos J, Prieto E, Román A, Soto de Ozaeta C, Nevado I, Richart A, Chica E, Loscertales J, Calabuig T, Benítez J, Outeiriño J.
    Sangre (Barc); 1996 Dec; 41(6):447-57. PubMed ID: 9148422
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Soyer N, Haznedaroğlu İC, Cömert M, Çekdemir D, Yılmaz M, Ünal A, Çağlıyan G, Bilgir O, İlhan O, Özdemirkıran F, Kaya E, Şahin F, Vural F, Saydam G.
    Turk J Haematol; 2017 Mar 01; 34(1):27-33. PubMed ID: 27094252
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O, Loch G, Schade U, von Wasielewski R, Schlué J, Kreipe H.
    J Pathol; 2005 Apr 01; 205(5):548-57. PubMed ID: 15726648
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
    Björkholm M, Hultcrantz M, Derolf ÅR.
    Best Pract Res Clin Haematol; 2014 Jun 01; 27(2):141-53. PubMed ID: 25189725
    [Abstract] [Full Text] [Related]

  • 15. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
    Bock O, Schlué J, Mengel M, Büsche G, Serinsöz E, Kreipe H.
    J Pathol; 2004 May 01; 203(1):609-15. PubMed ID: 15095485
    [Abstract] [Full Text] [Related]

  • 16. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
    Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F.
    Haematologica; 2005 Feb 01; 90(2):261-2. PubMed ID: 15710584
    [Abstract] [Full Text] [Related]

  • 17. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
    Nielsen I, Hasselbalch HC.
    Am J Hematol; 2003 Sep 01; 74(1):26-31. PubMed ID: 12949887
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T, GIMEMA CMD-Working Party.
    Haematologica; 2008 Mar 01; 93(3):372-80. PubMed ID: 18268279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.